NCBI PubMed Central
open access
Cost-effectiveness of nivolumab plus ipilimumab versus lenvatinib or sorafenib for unresectable hepatocellular carcinoma in China: a modeling study with price threshold analysis.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Development and Validation of Nomogram Predicting Survival in Chinese SCLC Patients#864709
- Sintilimab Combined With Lenvatinib in Local Advanced Hepatocellular Carcinoma#825554
- Proposal for Risk-Adjusted Surveillance Strategies in Extrahepatic Bile Duct Cancer with Cost-Effectiveness Validation: A Real-World Multi-institutional Cohort Analysis#425864
- Digitalized Surveillance Management for Liver Cancer Risk Population in Improving Eearly Diagnosis Efficancy in Chinese Population (dSEARCH)#966746
- Development and validation of a nomogram based on tumor margin irregularity and alpha-fetoprotein for predicting microvascular invasion in hepatocellular carcinoma.#360585
Record · ID 371750
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive